arrow_back Trending Legislation
Share share

Accelerating Research and Access to ALS Drugs

This law aims to accelerate research into Amyotrophic Lateral Sclerosis (ALS) and other rare neurodegenerative diseases. It facilitates access to investigational drugs for patients not eligible for clinical trials and supports the development of new therapies. This provides greater hope for improved quality of life and access to innovative treatments for individuals suffering from these conditions.
Key points
Authorizes grants for scientific research using data from expanded access to investigational drugs for ALS patients.
Establishes a public-private partnership to accelerate the development of therapies for rare neurodegenerative diseases.
Requires the Food and Drug Administration (FDA) to publish an action plan for fostering safe and effective drug development for ALS and other rare neurodegenerative diseases.
Authorizes $100 million annually for fiscal years 2022 through 2026 to carry out the Act.
article Official text account_balance Process page notifications_active Track this Bill
99%
VOTING RESULTS
2021-12-09
For 423
Against 3
Abstain 0
Full voting results open_in_new
gavel
Status:
Became Law
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Accelerating Access to Critical Therapies for ALS Act
Print number: HR 3537
Sponsor: Rep. Quigley, Mike [D-IL-5]
Process start date: 2021-05-25
Voting date: 2021-12-09
Meeting no: 1
Voting no: 415
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Accelerating Research and Access to ALS Drugs

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 3537.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-05-25.

What are the main provisions?

Key points include:

  • Authorizes grants for scientific research using data from expanded access to investigational drugs for ALS patients.
  • Establishes a public-private partnership to accelerate the development of therapies for rare neurodegenerative diseases.
  • Requires the Food and Drug Administration (FDA) to publish an action plan for fostering safe and effective drug development for ALS and other rare neurodegenerative diseases.
  • Authorizes $100 million annually for fiscal years 2022 through 2026 to carry out the Act.

What is the specific legal status?

The current status is Became Law.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Where is the official voting record?

The official roll call vote is recorded at: voting record

Who is the primary sponsor?

The primary sponsor is Rep. Quigley, Mike [D-IL-5].

What is the latest detailed status?

The latest detailed status is: Became Public Law No: 117-79.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

Analysis and Potential Impact of HR 3537

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health